FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W259318731> ?p ?o ?g. }

• W259318731 endingPage "196" @default.
• W259318731 startingPage "179" @default.
• W259318731 abstract "Abstract A patient suffering from acute lymphoblastic leukemia in the third progressive phase, refractory to the majority of available treatments, was given total-body irradiation of 800 r. dosage, after administration of methyl-nitro-imidazolyl-mercaptopurine (300 mg. daily for 4 days). One week after irradiation, he received an infusion of a mixture of equal parts of bone marrow from six donors (mother, sister, father and three brothers), a total of 5.8 x 1010 nucleated cells. Myeloid restoration began 2 weeks after the infusion and continued to progress rapidly. The reality of the graft was demonstrated by study of the erythrocytic antigens. Nearly all the erythrocytes found in the blood after 6 months belonged to the phenotype of one of the male donors. Studies of chromosomes and leukocyte sex chromatin suggested that a small proportion of leukocytes were being produced by the cells of one of the female donors. The patient was found to produce beta 2A, beta 2M and gamma globulins of the Inv type of the donors, suggesting that lymphoid cells may also have been successfully grafted. A skin graft from the male donor whose marrow graft had apparently been accepted was still perfectly intact 7 months after grafting, whereas the grafts from other donors were rejected, indicating a specific tolerance to tissues from this donor. Previous studies of compatibility between the recipient and the various donors by a histocompatibility test described by us, or by means of similarities in leukocyte antigens, indicated that the accepted donor had been antigenically more nearly compatible than the others. What appeared to be a secondary syndrome became manifest 1 week after marrow transfusion; it consisted of weight loss, digestive disorders (anorexia, nausea, vomiting, diarrhea), hepatic disturbances (hepatomegaly, increased serum concentrations of various enzymes), transient polyadenopathy (histologically composed of histiocytic proliferation and lymphocytic aplasia), desquamative erythrodermia, eosinophilia exceeding 50 per cent, and superinfection (including a probable miliary tuberculosis). The syndrome was controlled by careful symptomatic treatment; its intensity gradually abated. Reactivation of the secondary syndrome was accomplished by reinjection of leukocytes from the donor whose graft had been tolerated. This was controlled by Δ-1-cortisone and symptomatic treatment. The patient was still alive and in apparently complete hematologic remission from the leukemia 12 months after the treatment described above. Particular reasons for this success possibly include the absence of previous blood transfusions and the use of multiple marrow donors." @default.
• W259318731 created "2016-06-24" @default.
• W259318731 creator A5034727108 @default.
• W259318731 creator A5035753830 @default.
• W259318731 creator A5038986310 @default.
• W259318731 creator A5039988414 @default.
• W259318731 creator A5041441471 @default.
• W259318731 creator A5044659869 @default.
• W259318731 creator A5051165466 @default.
• W259318731 creator A5054482522 @default.
• W259318731 creator A5058235924 @default.
• W259318731 creator A5061711064 @default.
• W259318731 creator A5070877460 @default.
• W259318731 creator A5073073644 @default.
• W259318731 creator A5080259363 @default.
• W259318731 creator A5080377263 @default.
• W259318731 creator A5083780114 @default.
• W259318731 date "1965-02-01" @default.
• W259318731 modified "2023-09-26" @default.
• W259318731 title "Successful Allogenic Bone Marrow Transplantation in Man: Chimerism, Induced Specific Tolerance and Possible Anti-Leukemic Effects" @default.
• W259318731 cites W102215513 @default.
• W259318731 cites W140836417 @default.
• W259318731 cites W151784179 @default.
• W259318731 cites W2012203087 @default.
• W259318731 cites W2224860441 @default.
• W259318731 cites W2264269459 @default.
• W259318731 doi "https://doi.org/10.1182/blood.v25.2.179.179" @default.
• W259318731 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14267694" @default.
• W259318731 hasPublicationYear "1965" @default.
• W259318731 type Work @default.
• W259318731 sameAs 259318731 @default.
• W259318731 citedByCount "146" @default.
• W259318731 countsByYear W2593187312012 @default.
• W259318731 countsByYear W2593187312013 @default.
• W259318731 countsByYear W2593187312014 @default.
• W259318731 countsByYear W2593187312017 @default.
• W259318731 countsByYear W2593187312018 @default.
• W259318731 countsByYear W2593187312019 @default.
• W259318731 countsByYear W2593187312020 @default.
• W259318731 countsByYear W2593187312021 @default.
• W259318731 countsByYear W2593187312022 @default.
• W259318731 countsByYear W2593187312023 @default.
• W259318731 crossrefType "journal-article" @default.
• W259318731 hasAuthorship W259318731A5034727108 @default.
• W259318731 hasAuthorship W259318731A5035753830 @default.
• W259318731 hasAuthorship W259318731A5038986310 @default.
• W259318731 hasAuthorship W259318731A5039988414 @default.
• W259318731 hasAuthorship W259318731A5041441471 @default.
• W259318731 hasAuthorship W259318731A5044659869 @default.
• W259318731 hasAuthorship W259318731A5051165466 @default.
• W259318731 hasAuthorship W259318731A5054482522 @default.
• W259318731 hasAuthorship W259318731A5058235924 @default.
• W259318731 hasAuthorship W259318731A5061711064 @default.
• W259318731 hasAuthorship W259318731A5070877460 @default.
• W259318731 hasAuthorship W259318731A5073073644 @default.
• W259318731 hasAuthorship W259318731A5080259363 @default.
• W259318731 hasAuthorship W259318731A5080377263 @default.
• W259318731 hasAuthorship W259318731A5083780114 @default.
• W259318731 hasBestOaLocation W2593187311 @default.
• W259318731 hasConcept C126322002 @default.
• W259318731 hasConcept C147483822 @default.
• W259318731 hasConcept C16685009 @default.
• W259318731 hasConcept C188280979 @default.
• W259318731 hasConcept C202965653 @default.
• W259318731 hasConcept C203014093 @default.
• W259318731 hasConcept C2776694085 @default.
• W259318731 hasConcept C2776755627 @default.
• W259318731 hasConcept C2778461978 @default.
• W259318731 hasConcept C2778880498 @default.
• W259318731 hasConcept C2780007613 @default.
• W259318731 hasConcept C2911091166 @default.
• W259318731 hasConcept C71924100 @default.
• W259318731 hasConceptScore W259318731C126322002 @default.
• W259318731 hasConceptScore W259318731C147483822 @default.
• W259318731 hasConceptScore W259318731C16685009 @default.
• W259318731 hasConceptScore W259318731C188280979 @default.
• W259318731 hasConceptScore W259318731C202965653 @default.
• W259318731 hasConceptScore W259318731C203014093 @default.
• W259318731 hasConceptScore W259318731C2776694085 @default.
• W259318731 hasConceptScore W259318731C2776755627 @default.
• W259318731 hasConceptScore W259318731C2778461978 @default.
• W259318731 hasConceptScore W259318731C2778880498 @default.
• W259318731 hasConceptScore W259318731C2780007613 @default.
• W259318731 hasConceptScore W259318731C2911091166 @default.
• W259318731 hasConceptScore W259318731C71924100 @default.
• W259318731 hasIssue "2" @default.
• W259318731 hasLocation W2593187311 @default.
• W259318731 hasLocation W2593187312 @default.
• W259318731 hasOpenAccess W259318731 @default.
• W259318731 hasPrimaryLocation W2593187311 @default.
• W259318731 hasRelatedWork W1983836789 @default.
• W259318731 hasRelatedWork W2072899656 @default.
• W259318731 hasRelatedWork W2348031615 @default.
• W259318731 hasRelatedWork W2354953665 @default.
• W259318731 hasRelatedWork W2371378237 @default.
• W259318731 hasRelatedWork W2465571338 @default.
• W259318731 hasRelatedWork W2757404963 @default.
• W259318731 hasRelatedWork W4238201290 @default.

• next